Unum Therapeutics Inc. (UMRX) EPS Estimated At $-0.33

July 14, 2018 - By Yee Bell

Analysts expect Unum Therapeutics Inc. (NASDAQ:UMRX) to report $-0.33 EPS on August, 13.After having $-0.66 EPS previously, Unum Therapeutics Inc.’s analysts see -50.00 % EPS growth. The stock increased 5.48% or $0.84 during the last trading session, reaching $16.16. About 78,054 shares traded. Unum Therapeutics Inc. (NASDAQ:UMRX) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company has market cap of $482.20 million. The Company’s lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. It currently has negative earnings. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers.

More important recent Unum Therapeutics Inc. (NASDAQ:UMRX) news were published by: Globenewswire.com which released: “Unum Therapeutics Joins Russell 3000® Index” on June 25, 2018, also Benzinga.com published article titled: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading”, Nasdaq.com published: “Unum Therapeutics to Present Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the …” on July 12, 2018. More interesting news about Unum Therapeutics Inc. (NASDAQ:UMRX) was released by: Bizjournals.com and their article: “Goodwin dominates this year’s record batch of Mass. biotech IPOs” with publication date: July 03, 2018.

Unum Therapeutics Inc. (NASDAQ:UMRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.